tbuckley/cabot-search huggingface dataset:
Weekly paclitaxel as second/third line chemotherapy for advanced and metastatic non-small cell lung cancer
Authors: C. Camps, C. Caballero, J. Garde, A. Juarez, A. Blasco, A. Berrocal
Journal: Journal of Clinical Oncology (2004)

7311 Background: to evaluate the efficacy and toxicity of weekly paclitaxel as second or third line chemotherapy in patients with advanced or metastatic NSCLC Methods: It's a descriptive and retrospective study of patients with advanced or metastatic NSCLC treated in second or third line chemotherapy with weekly Paclitaxel (60 – 80 mg/m2) until progression or unacceptable toxicity. The primary objectives were to evaluate the efficacy and toxicity of this scheme Results: Between January 2001 and November 2003, a total of 37 patients (35 males and 2 women) with median age of 63,24 year– (between 27 and 82) diagnosed of NSCLC were studied. The histologycal types were 17 patients (45,9%) adenocarcinoma, 12 patients (32,4%) Squamous cell, 7 patients (18'9%) undiffereciated cell and 1 patient (2,7%) adenosquamous. Sixteen patients (43,2%) had stage IIIB disease, 2 (5,4%) stage IIIA and 19 patients (51,4%) stage. IV disease. The metastasis was located in 6 patients (33,3%) in the liver, 4 (22,2%) adrenal gland and 3 patients (16,6%) lung and bone. Thirty-six patients (97,3%) received a first chemotherapy line based on platinum and 1 patient (2,7%) without platinum. All patients were treated with weekly paclitaxel (60 – 80 mg/m2) at second line 34 patients (91,9%) and at third line 3 patients (8,1%).The median number of courses of weekly paclitaxel for patient was 3 (1–11). All patients were evaluated for responses, one patient (2,7%) presented complete response, 2 (5,4%) partial response, 10 (27%) stable disease and 19 (51,4%) progressive disease. The median survival time was 38 weeks (13,6–62,4) and the median time to disease progression was 12 weeks (10,45–13,55). The patients presented well tolerated weekly paclitaxel, 22 patients (59'5%) had no hematologic toxicity, 11 (29,7%) anemia G2/G3, 3 (8,1%) severe neutropenia and 1 patient (2,7%) severe thrombocytopenia. Relevant non hematologic toxicity was sensory neuropathy 15 patients (40,54%) and alopecia 13 (35,13%). Two patients had hypersensibity reaction. Conclusions: These data point out weekly paclitaxel as an active and well tolerated agent at second/ third line chemotherapy for advanced NSCLC No significant financial relationships to disclose.
Effect of Dithiothreitol on Plasma Membrane Intramembranous Particle Topography in BALB/c 3T3 and Simian Virus-Transformed 3T3 Cells and Plasma Membrane Vesicles
Authors: R E Scott, P B Maercklein
Journal: JNCI Journal of the National Cancer Institute (1980)

A statistical analysis of plasma membrane intramembranous particle topography was performed on purified 3T3 and simian virus (SV)-transformed 3T3 plasma membrane vesicles and on intact 3T3 and SV3T3 cells. The results show that intramembranous particles were more aggregated in intact 3T3 cells than in intact SV3T3 cells. By contrast, in purified plasma membrane vesicles intramembranous particles were significantly more aggregated in SV3T3 than in 3T3 preparations. These unexpected results suggest that intramembranous particle topography is selectively altered in SV3T3 plasma membranes during the membrane vesicle isolation procedure. Inasmuch as the disulfide-reducing agent dithothreitol (DTT) was used to isolate membranes, tests were done to determine if DTT would preferentially affect particle topography in intact SV3T3 cells. Exposure of intact SV3T3 cells to 10 or 50 mM DTT induced intramembranous particle aggregation but had no effect on intact 3T3 cells. Preliminary studies also showed that other sulfhydrylreactive compounds preferentially induced particle aggregation in SV3T3 specimens. These observations suggest that the state of cross-linking of membrane-associated proteins by disulfide bonding influences intramembranous particle topography and that differences exist in plasma membrane-associated sulfhydryl proteins in nontransformed and transformed cells.
Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) combination therapy in newly diagnosed acute promyelocytic leukemia (APL)
Authors: A. M. Tsimberidou, H. M. Kantarjian, G. Garcia-Manero, C. Koller, D. M. Jones, M. J. Keating, E. Estey
Journal: Journal of Clinical Oncology (2006)

6503 Background: ATRA and anthracyclines provide durable remissions in patients with untreated APL. As 2 O 3 has improved outcomes in untreated and relapsed/refractory APL. The aim of this study was to determine the rates of complete response (CR) and molecular remission with ATRA and As 2 O 3 combination therapy in untreated APL. Methods: From 2/02 to 1/06, 53 patients with untreated APL received ATRA 45 mg/m 2 daily and As 2 O 3 0.15 mg/kg IV 1-hr infusion daily starting on day 10. Patients with WBC&gt;10×10 9 /L also received gemtuzumab ozogamicin (GO) 9 mg/m 2 on day 1 and/or idarubicin 12 mg/m 2 on days 1–4. Patients in CR received As 2 O 3 0.15 mg/kg IV on days 1–5 weekly for 4 weeks on and 4 weeks off and ATRA 45 mg/m 2 daily for 2 weeks on and 2 weeks off (for 28 weeks). Polymerase chain reaction (PCR) testing for PML-RARα (sensitivity level, 10 −4 ) was performed every 3 months from CR for 2 years. Patients with molecular relapse received GO 9 mg/m 2 once monthly for 3 months in addition to ATRA and As 2 O 3 as in postremission therapy. If PCR became negative, only the single dose of GO was given. Results: The median age was 46 years; and 20% of patients were Sanz low risk, 40% intermediate, and 40% high risk. The CR rate was 91% (low risk 91%, intermediate 95%, high risk 86%). The median follow-up in surviving patients was 1.6 years. Six patients died during induction, and 2 died in CR from other cancers. The 1-yr survival rate was 88%. Three patients relapsed (at 9, 9, and 16 months). The 1-yr failure-free survival (FFS) rate in responding patients was 94% (high risk 86%, other risk 100%). Molecular remission rates are shown in the Table . Grade 3–4 nonhematologic toxicities were infections (n=16), neurologic (n=4), cardiac arrhythmias (n=4), APL differentiation syndrome (n=4), and headache (n=2). Conclusions: ATRA plus As 2 O 3 results in high rates of CR, molecular remission, FFS, and survival and is an alternative to ATRA and idarubicin combination therapy in low-risk APL. [Table: see text] No significant financial relationships to disclose.
춘계학술대회 : 구연 ; 전격성 간부전의 원인, 임상양상, 사망예견인자 -이식센터가 있는 한 3차 의료기관의 사례-
Authors: 허내윤, 임영석, 정석원, 이윤선, 김강모, 정영화, 이영상, 서동진
Journal: Clinical and Molecular Hepatology (2005)

배경/목적: 전격성 간부전은 수일 내지 수 주 내에 대부분의 환자들이 사망에 이르는 치명적인 질환으로서, 그 원인은 국가별, 시대별로 다를 것으로 추정되고, 최근에는 간이식술등 적극적인 치료의 적용이 가능해짐에 따라 생존률도 향상된 것으로 추정된다. 그러나, 우리나라에서 전격성 간부전의 원인과, 임상경과, 간이식후 생존률 및 예후인자에 대해 조사된 자료는 아직 빈약하다. 이에, 본 연구자 등은 간이식센타를 운영하고 있는 한 3차 의료기관에서 전격성 간부
Abstract 12582: Genetically Reduced High-Density Lipoprotein Cholesterol and Risk of Type 2 Diabetes: A Mendelian Randomization Study
Authors: Christiane L Haase, Anne Tybjaerg-Hansen, Borge G Nordestgaard, Ruth Frikke-Schmidt
Journal: Circulation (2014)

Introduction: Epidemiologically low levels of high-density lipoprotein (HDL) cholesterol consistently associate with increased risk of type 2 diabetes. The causal nature of this association is unclear. Hypothesis: Using Mendelian randomization, we tested whether low levels of HDL cholesterol causally influence type 2 diabetes. Methods: In a prospective study of 47,627 individuals from the general population, we tested whether low HDL cholesterol predicted risk of type 2 diabetes. Using a combined genotype score or allele numbers of five HDL genes, we tested whether genetic variants associated with low HDL cholesterol levels also associated with an increased risk of type 2 diabetes. Results: Risk of type 2 diabetes increased with decreasing levels of HDL cholesterol (P for trend=3x10-58). HDL cholesterol decreasing gene scores and allele numbers associated with up to -13% and -20% decreases in HDL cholesterol levels. The corresponding theoretically predicted hazard ratios (HRs) for type 2 diabetes were 1.4...
OC-076 Outcomes after curative treatment for oesophago-gastric cancer in the elderly: Abstract OC-076 Table 1
Authors: G Chadwick, O Groene, R Hardwick, T Crosby, S Riley, D Cromwell
Journal: Gut (2015)

<h3>Introduction</h3> 60% of Oesophago-Gastric (OG) cancers are diagnosed in patients aged 70 or over.<sup>1</sup>The 2014 National Oesophago-Gastric cancer audit (NOGCA) report found that elderly patients were equally likely to be managed with curative intent (after adjusting for known confounders), but it is not clear whether their short term outcomes are comparable. In this study we investigated whether age was associated with outcomes after curative surgery. <h3>Method</h3> This study uses data collected for the NOGCA, focusing on patients diagnosed between 1<sup>st</sup>April 2011 and 31<sup>st</sup>March 2013 who had a curative resection before the 1<sup>st</sup>January 2014. Outcomes considered were 90 day mortality and complication rates. Results were adjusted for known confounders: sex, TNM stage at diagnosis, performance status, comorbidities and ASA grade. <h3>Results</h3> Overall 13,334 patients aged 70 or over were diagnosed with OG cancer. 28.8% of these were managed with curative intent, such that 1,001 oesophagectomies and 1,039 gastrectomies were performed in patients aged 70 or over. Patients aged 70 or over undergoing a curative oesophagectomy had higher 90-day mortality and complication rates than younger patients, this difference was maintained after adjusting for known confounders (Table 1). For gastrectomies there was no significance in outcomes according to the age of patient. <h3>Conclusion</h3> Elderly patients undergoing an oesophagectomy had significantly worse outcomes compared to younger patients. Therefore efforts need to be made to reduce their higher risk to levels achieved by younger patients in future. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Chadwick G, Taylor A, Groene O, <i>et al</i>. The National Oesophago-Gastric Cancer Audit. An audit of the care received by people with Oesophago-gastric cancer in England and Wales. 2014 Annual Report. In: HSCIC, ed., 20142014
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001–01 CHOC)
Authors: J. C. Barbare, O. Bouché, F. Bonnetain, C. Lombard-Bohas, R. Faroux, L. Dahan, J. L. Raoul, S. Cattan, A. Lemoine, J. F. Blanc
Journal: Journal of Clinical Oncology (2005)

4036 Background. The antitumor effects of somatostatin analogues in hepatocellular carcinoma (HCC) remain controversial. This trial was designed to look for a benefit in overall survival (OS) of long-acting octreotide in patients with advanced HCC. Methods. From July 2002 to October 2003, 272 patients with HCC not suitable for surgery, percutaneous ablation or chemoembolization were included in a multicentric, placebo-controlled phase III trial. HCC was histologically proven or diagnosed by the association of cirrhosis, serum alpha-foetoprotein > 500 μg/L and typical imaging findings. Were excluded patients with hypoglycaemia, unstable diabetes mellitus, extra hepatic life-threatening disease, CLIP score > 3, serum creatinin > 120 μmol/L, prothrombin activity < 50%, platelets count < 50,000 /μL, or with symptomatic cholelithiasis. Patients were randomized between octreotide (O) and placebo (P) arms, stratified on center and CLIP score. Patients received a monthly intramuscular injection of placebo or 30 mg long-acting octreotide. The sample size was calculated with an expected median OS of 12.0 months (O arm) vs 7.7 months (P arm) (type I error = 5%, type II = 10%). An interim analysis was planned after the occurrence of 150 deaths. Median survival was estimated by the Kaplan-Meier method. Results. In April 2004, median OS were 6.5 (4.7–7.0) months in the O arm and 7.3 (5.5–8.6) months in the P arm. Symptomatic hypoglycaemia was the only adverse event observed in treated patients (0.7%). These results were submitted to an IDMC, which recommended: to stop inclusion and to carry on treatment until the end point for the final analysis (October 15 2004). Conclusions. No survival benefit was suggested by the results of this interim analysis. The final results will be presented at the meeting. Sponsoring and main financing by Novartis Pharma. No significant financial relationships to disclose.
Interaction Between Aromatic Diamidines and Nucleic Acids: Possible Implications for Chemotherapy
Authors: D R Makulu, T P Waalkes
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Interaction Between Aromatic Diamidines and Nucleic Acids: Possible Implications for Chemotherapy Get access David R. Makulu, David R. Makulu Search for other works by this author on: Oxford Academic PubMed Google Scholar T. Phillip Waalkes T. Phillip Waalkes Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 2, February 1975, Pages 305–309, https://doi.org/10.1093/jnci/54.2.305 Published: 01 February 1975 Article history Received: 04 February 1974 Revision received: 15 October 1974 Accepted: 25 October 1974 Published: 01 February 1975
What causes cam deformity and femoroacetabular impingement: still too many questions to provide clear answers
Authors: Rintje Agricola, Harrie Weinans
Journal: British Journal of Sports Medicine (2015)

Cam deformities of the femoral head contribute to femoroacetabular impingement (FAI) and correlates strongly with development of osteoarthritis.1 Surgery on patients with FAI is performed with increasing frequency; it is unknown whether this prevents osteoarthritis in later life.2 As cam deformity is triggered during late puberty by impact loading of the hip, it is important to elucidate the aetiology of cam deformity.

Sex, genetics and physical activity appear to influence whether or not a cam deformity develops. The prevalence of cam deformity is as high as 89% in athletes participating in activities that result in impact loading of the hip as compared to only 9% in non-athletic controls.3 What explains these differences? More than 40 years ago, Murray and Duncan4 recognised that by the loads applied to the hip during skeletal growth influenced, at least in part, development of a cam deformity. They postulated that cam deformity resulted from a mild undiagnosed slipped capital femoral epiphysis (SCFE) in young athletes but recent studies in adolescent athletes suggest SCFE is not involved.5 Hence, cam deformity result from bone adaptation in response to vigorous hip loading, which means that it should be …
Possibility of Distinction Between Malignant and Nonmalignant Cells by Transplantation Into Chick Blastoderms; Further Evidence From Animal and Human Biopsy Specimens2
Authors: M. Mareel, L. Vakaet, L. De Ridder, M. Debrabander, A. Bozzi, J. Deman
Journal: JNCI Journal of the National Cancer Institute (1974)

Biopsy specimens of 4 solid tumors from animals, 3 malignant ascitic effusions, 2 nodules obtained by injection of malignant ascites cells, and 15 human lesions were transplanted into defects in the lower layers of young chick blastoderms. Histologic examination of the cultures after 24 hours incubation showed that the lower layer was completely repaired at the site of all nonmalignant cells. However, repair of this layer was inhibited at the site of all malignant cells. These results confirm that the chick blastoderm is a useful experimental device to distinguish between malignant and nonmalignant cells.
p27<sup>kip1</sup> Protein Expression Correlates With Survival in Myxoid and Round-Cell Liposarcoma
Authors: Andre M. Oliveira, Antonio G. Nascimento, Scott H. Okuno, Ricardo V. Lloyd
Journal: Journal of Clinical Oncology (2000)

The p27(kip1) protein (p27) is a cyclin-dependent kinase inhibitor that has been shown to be an independent prognostic factor in a variety of human neoplasms. Low expression of p27 tends to occur in more aggressive neoplasms. The role of p27 as an independent prognostic factor in the spectrum of myxoid and round-cell liposarcomas has not been examined.Forty-seven cases of myxoid and round-cell liposarcomas were examined. Clinicopathologic features and immunohistochemical expression of p27 and Ki-67 antigen were studied in all cases. Survival analysis was performed using the log-rank test and the Cox multivariate regression model.The male:female ratio was 1. 4:1, and the mean age at diagnosis was 45 years. The tumors were located in the lower extremities (94%) and retroperitoneum (6%). The median tumor size was 13.5 cm. The median follow-up was 6.3 years, and the overall 5- and 10-year survival rates were 76% and 67%, respectively. Low expression of p27 was identified in 34 cases (72%) and correlated with decreased metastasis-free (P =.026) and overall survival (P =.008). In a multivariate analysis, only round-cell differentiation and low expression of p27 independently predicted decreased metastasis-free and overall survival.p27 expression predicts the clinical behavior of myxoid and round-cell liposarcomas, even in neoplasms with few or no round-cell differentiation.
P0302 : Constitutive gp130 activation accelerates transformation of proliferating human hepatocytes via increased levels of oxidative stress
Authors: I. Gil-Ibanez, D. Heim, J. Herden, A.C. Parplys, K. Borgmann, D. Schmidt-Arras, A.W. Lohse, S. Rose-John, H. Wege
Journal: Journal of Hepatology (2015)
Masking of Receptors for Sheep Erythrocytes on Human T-Lymphocytes by Sera From Breast Cancer Patients 2
Authors: R. H. Whitehead, G. P. Roberts, J. Thatcher, C. Teasdale, L. E. Hughes
Journal: JNCI Journal of the National Cancer Institute (1977)

Sera from 140 breast cancer patients and 38 controls were tested for their ability to inhibit sheep erythrocyte (E) rosette formation by normal, allogeneic lymphocytes. Inhibition of rosette formation by greater than 20% was found with 65% of stage I sera, 91% of stage II sera, 56% of stage III sera, and all stage IV sera. In contrast, only 13% of control sera was inhibitory. The inhibitory factor was found to bind to only a proportion of T-lymphocytes and could be removed from these lymphocytes by mild proteolytic digestion or extended washing. Examination of the properties of the inhibitory factor indicated that it differed from other substances that reportedly inhibited E-rosette formation.
Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk
Authors: F. Kabbinavar, A. Zurlo, C. Irl, H. Hurwitz
Journal: Journal of Clinical Oncology (2006)

3539 Background: It has been reported that patients with mCRC obtain benefit from BV independent of baseline risk factor status. Analysis of 3,825 patients treated with 5-FU/LV in 19 randomised trials conducted by Koehne et al. [Ann Oncol 2002;13:308–17] showed that four baseline prognostic variables can be used to categorise patients into three prognostic groups with different overall survival (OS). We have retrospectively applied this model to data from a phase III trial of first-line IFL with placebo or BV (AVF2107g). Methods: Data on ECOG performance status (PS), tumour site, alkaline phosphatase (AP) levels and white blood cell counts (WBC) were prospectively collected for the 813 patients randomised in AVF2107g. These data were retrospectively used to categorise patients in the IFL/placebo (n=411) and IFL/BV (n=401; data not available for 1 patient) arms into three risk groups: Low - ECOG PS 0/1, one tumour site; intermediate - ECOG PS 0/1, &gt;1 tumour site, AP level &lt;300U/L, or ECOG PS &gt;1, low WBC count, one tumour site; high - ECOG PS 0/1, &gt;1 tumour site, AP level &gt;300U/L, or ECOG PS &gt;1, high WBC count, &gt;1 tumour site. Median OS and PFS in these groups were calculated. Results: OS (Table) and PFS were significantly longer in the IFL/BV groups compared to the IFL/placebo groups, as well as in the lower compared to the higher risk groups in both arms. Conclusions: The analysis supports previous analyses showing that adding BV to IFL improves OS independent of baseline patient risk. Furthermore, high-risk patients, who are less likely to benefit from IFL, benefit from IFL/BV. The model developed by Koehne et al may be applicable to regimens other than 5-FU/LV and validates the efficacy of BV first line in mCRC. [Table: see text] [Table: see text]
Prognostic significance of albumin level in patients undergoing elective surgery for colon cancer
Authors: S. Kosmider, S. Shedda, I. Faragher, I. Jones, P. Gibbs
Journal: Journal of Clinical Oncology (2008)

15110 Background: New prognostic markers for pts (patients) undergoing surgery for colorectal cancer are urgently sought. Recent small series suggest that serum albumin, a marker of inflammation, is a potentially useful biomarker. However, the stage specific impact of a low albumin level (<35) has not been adequately explored. The possibility that a low albumin level is a surrogate of other adverse prognostic features has also yet to be excluded. Method: We examined our prospective multi-centre colorectal cancer database from January 2003 - August 2007 to determine the relationship between albumin level and tumour stage, ASA score, ECOG performance status, co-morbidity data (including diabetes), and survival outcomes. Results: 378 pts who had undergone surgery for stage I (n=72), II (n=175) or III (n=131) colon cancer were identified. 46 pts who had undergone emergency surgery were excluded. Median follow-up was 20.5 months. When individual stages were analysed, the survival curves overlapped for stage I cancers, however there was a significant difference for stage II cancers for PFS (p < 0.0001) and OS (p<0.0001). A trend was observed for stage III cancers for PFS (p=0.123) and OS (p=0.227), with 64% of pts with a normal albumin progression free at 21 months versus 43% of patients with a low albumin. For all pts albumin was a significant predictor of progression free (p=0.001) and overall survival (p<0.001). There was no significant relationship between albumin and markers of general health, or co-morbidity. Conclusion: Our data suggests that albumin level is an independent prognostic variable for tumour recurrence and survival for stage B colon cancer, and possibly for stage C cancer. Albumin level is a simple and potentially useful prognostic marker, but this needs to be validated in an adequately powered prospective study. No significant financial relationships to disclose.
Association of Statin Use and Reduced Risk of Lower-Extremity Amputation Among Patients With Diabetes: A Nationwide Population-Based Cohort Observation
Authors: Tsung-Lin Yang, Liang-Yu Lin, Chin-Chou Huang, Po-Hsun Huang, Shing-Jong Lin, Jaw-Wen Chen, Wan-Leong Chan, Hsin-Bang Leu
Journal: Diabetes Care (2016)

Diabetes mellitus (DM) is a disease entity associated with metabolic abnormality and systemic vascular inflammation, causing microvascular as well as macrovascular organ damage. Statins are widely used for the management of dyslipidemia. Beyond the lipid-lowering effect, statins were found to have many pleiotropic effects, such as anti-inflammatory and antiatherogenic effects. We conducted a nationwide population-based cohort study to investigate the relationship between statin use and the risk of lower-extremity amputation in patients with DM. A database from the Taiwan National Health Research Institutes was used, and subjects with DM were identified using ICD-9 coding. The study cohort was separated to statin group and control groups. The observation end point was any lower-extremity amputation.

Out of a total of 38,973 patients with DM, 20,254 (51.97%) patients taking statins were compared with those not taking statins. During a mean follow-up of 5.2 …